Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis

Zabala-Findlay, Alex; Penny, Lewis K.; Lofthouse, Richard A.; Porter, A.J.; Palliyil, Soumya; Harrington, Charles R.; Arastoo, Mohammad

doi:10.3390/cells12081184

Cited by 12 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main focus of the study is to examine the relationships between pre and post diseases, as well as their relationship with AD/dementia, using visual outputs obtained through the PCG. PCG outputs were obtained using the "plotly" package in R Studio 4.3.0 40 . Other graphical representations were created using Microsoft Power BI program.…”

Section: Methodsmentioning

confidence: 99%

Insights from Turkey's big data: unraveling the preventability, pathogenesis, and risk management of Alzheimer's disease (AD)

Yiğit,

Ata,

Dinçer

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Extensive research into dementia has more recently honed in on several key areas. These areas include the advancement of techniques such as the accumulation of amyloid-β and tau proteins, the monitoring of cerebral hypometabolism rates etc. The primary objective of this study is to explore the intricate interplay between Alzheimer's disease (AD)—other dementias (D) and various chronic illnesses in terms of time, intensity, and connectivity. In this context, we retrospectively examined data of 149,786 individuals aged 65 and above who received diagnoses of AD and D in the year 2020. At first, logistic regression (LR) analysis has been made with “sex”, “age” and “foreigner” (citizenship status) independent variables for AD and D. The LR models shows that while “sex” and “age” variables have a small rate on the risk of developing AD/D, it is detected that being a foreigner increase the risk of AD and D as 69.8% and 88.5% respectively. Besides, the LR models have middle-level success prediction rate for both of the two dependent variables. Additionally, we used the parallel coordinates graphs method within the R Studio to visualize their relationships and connections. The findings of this investigation strongly suggest that AD/D don’t stand as isolated conditions, but rather stem from intricate interactions and progressive processes involving diverse chronic diseases over time. Notably, ailments including hypertension, coronary artery disease, diabetes, hyperlipidemia, and psychological disorders, contribute substantially to the emergence of both AD and D. This study highlights that the fight against AD/D can only be possible with next-generation prophylactic interventions that can predict and manage risks. Such an approach holds the potential to potentially lower AD and dementia to levels that are amenable to treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Insights from Turkey's big data: unraveling the preventability, pathogenesis, and risk management of Alzheimer's disease (AD)

Yiğit,

Ata,

Dinçer

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand

Thanapornsangsuth,

Booncharoen,

Khieukhajee

et al. 2024

Alzheimer's & Dementia

View full text Add to dashboard Cite

INTRODUCTIONPlasma phosphorylated tau (p‐tau)217 is a promising biomarker for Alzheimer's disease (AD) diagnosis, but its clinical implementation remains challenging. We propose a strategy based on Bayes’ theorem and test it in real‐life memory clinics.METHODSMemory clinic patients were evaluated by neurocognitive specialists for prespecified diagnosis and subsequently underwent blood collection for p‐tau217, cerebrospinal fluid, or amyloid positron emission tomography. Using cross‐validation, the Bayesian approach (pretest probability × individualized likelihood ratio) was compared to other models for AD diagnosis.RESULTSThe Bayesian strategy demonstrated an area under the receiver operating characteristic curve (AUC) of 0.98 (95% confidence interval [CI]: 0.96–1.0), significantly outperforming multivariable logistic regression (p‐tau217, age, apolipoprotein E; AUC 0.95, p = 0.024) and p‐tau217 alone (AUC = 0.94, p = 0.007). When applying the two‐threshold approach, the Bayesian strategy yielded an accuracy of 0.94 (95% CI: 0.88–1.0) without requiring confirmatory tests in 62.9% of the iterations.DISCUSSIONThe Bayesian strategy offers an effective and flexible approach to address the limitations of plasma p‐tau217 in clinical practice.Highlights Incorporating pretest probability into the interpretation of plasma phosphorylated tau (p‐tau)217 improves the diagnostic performance significantly. The strategy could obviate the need for confirmatory testing in most of the patients. Plasma p‐tau217 proves useful as a biomarker for Alzheimer's disease in low‐ and middle‐income country such as Thailand.

show abstract

Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta‐analysis

Khalafi,

Dartora,

McIntire

et al. 2024

Alzheimer's & Dementia

View full text Add to dashboard Cite

Our review summarizes the diagnostic accuracy of plasma and cerebrospinal fluid (CSF) phosphorylated tau 217 (p‐tau217) in detecting amyloid and tau pathology on positron emission tomography (PET). We systematically reviewed studies that reported the diagnostic accuracy of plasma and CSF p‐tau217, searching MEDLINE/PubMed, Scopus, and Web of Science through August 2024. The accuracy of p‐tau217 in predicting amyloid and tau pathology on PET was evaluated in 30 studies. Both plasma and CSF p‐tau217 effectively detect amyloid and tau PET deposition. Plasma p‐tau217 showed 82% sensitivity for detecting amyloid and 83% for tau, with 86% and 83% specificity, respectively. CSF p‐tau217 had 79% sensitivity for amyloid and 91% for tau, with 91% and 84% specificity. p‐tau217 effectively identifies Alzheimer's disease (AD) pathology. Plasma p‐tau217 was comparable to CSF p‐tau217 in detecting amyloid deposition on PET. Despite being less sensitive for detecting tau deposition on PET, plasma p‐tau217 can be an efficient screening tool for underlying AD pathology.Highlights Plasma phosphorylated tau 217 (p‐tau217) serves as a viable biomarker alternative to cerebrospinal fluid p‐tau217 due to the strong concordance between their results. Plasma p‐tau217 accurately identifies amyloid and tau positron emission tomography (PET) positivity, exhibiting a low rate of false negatives and positives, thereby establishing it as a reliable diagnostic tool for Alzheimer's disease (AD). Plasma p‐tau217 demonstrates slightly higher accuracy in predicting amyloid PET positivity compared to tau PET positivity. Plasma p‐tau217 demonstrates higher predictive accuracy in detecting AD pathology among cognitively impaired individuals, compared to cognitively unimpaired individuals, suggesting its enhanced utility as a diagnostic biomarker in clinical settings.

show abstract

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis

Cited by 12 publications

References 45 publications

Insights from Turkey's big data: unraveling the preventability, pathogenesis, and risk management of Alzheimer's disease (AD)

Insights from Turkey's big data: unraveling the preventability, pathogenesis, and risk management of Alzheimer's disease (AD)

The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand

Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta‐analysis

Contact Info

Product

Resources

About